Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Within the high-risk cluster, vitamin D3 was lowest, while BMI, triglycerides and BDNF were highest.
Source: Development of multisystem biomarker signatures. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts
Study design awaiting verification · Age and Ageing · 2026
Original publication title
An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts
© The Author(s) 2026. Published by Oxford University Press on behalf of the British Geriatrics Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Global population ageing is progressing at an unprecedented rate. Early identification of subpopulations at risk of chronic diseases could mitigate deteriorating health and increasing health service use, while revealing key biological cues and therapeutic targets. We hypothesised that a multisystem biomarker signature could identify future chronic disease trajectories, multimorbidity, functional decline and mortality.
Source: BackgroundAbstract: What methods does the paper describe?
Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland. Probabilistic clustering classified participants as belonging to one of three biomarker signatures at baseline. Biomarker signatures were designated as low, medium and high risk based on relative levels of biomarker dysregulation within the signatures and previously described associations with chronic disease and mortality. These biomarker signatures were utilised to predict 4-year functional decline; 8-year cardiovascular disease (CVD), diabetes, frailty, disability and 12-year mortality.
Results were validated in a US cohort (n = 3914).
Source: MethodsAbstract: Results
Low (58.5%), medium (9.2%) and high-risk (32.3%) biomarker signatures were identified in the cohort from Ireland. The high-risk signature was associated with higher 12-year mortality (HR: 1.89, P < .001); higher 8-year incidence of CVD, diabetes, multimorbidity, frailty and disability (OR range: 1.46 to 2.49. P < .05); and lower 4-year physical function (P < .01). Findings were corroborated in the US cohort. We identified and tracked 6 disease classes over 8 years: healthy, arthritis, diabetes/angina, hypothyroid/osteoporosis/respiratory, vision/anxiety/CVD and multisystem. Associations between the high-risk biomarker signature and two of the five 8-year incident disease classes were observed, implicating dysregulated immune and cardiometabolic pathways.
Source: ResultsAbstract: Conclusions
This study provides evidence that biomarker signatures and profiling of disease patterns can be used to risk stratify and identify ageing subpopulations that would benefit most from targeted preventative or secondary intervention strategies.
Source: ConclusionsAuthors’ abstract
Abstract
Background
Global population ageing is progressing at an unprecedented rate. Early identification of subpopulations at risk of chronic diseases could mitigate deteriorating health and increasing health service use, while revealing key biological cues and therapeutic targets. We hypothesised that a multisystem biomarker signature could identify future chronic disease trajectories, multimorbidity, functional decline and mortality.
Methods
Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland. Probabilistic clustering classified participants as belonging to one of three biomarker signatures at baseline. Biomarker signatures were designated as low, medium and high risk based on relative levels of biomarker dysregulation within the signatures and previously described associations with chronic disease and mortality. These biomarker signatures were utilised to predict 4-year functional decline; 8-year cardiovascular disease (CVD), diabetes, frailty, disability and 12-year mortality.
Results were validated in a US cohort (n = 3914).
Results
Low (58.5%), medium (9.2%) and high-risk (32.3%) biomarker signatures were identified in the cohort from Ireland. The high-risk signature was associated with higher 12-year mortality (HR: 1.89, P < .001); higher 8-year incidence of CVD, diabetes, multimorbidity, frailty and disability (OR range: 1.46 to 2.49. P < .05); and lower 4-year physical function (P < .01). Findings were corroborated in the US cohort. We identified and tracked 6 disease classes over 8 years: healthy, arthritis, diabetes/angina, hypothyroid/osteoporosis/respiratory, vision/anxiety/CVD and multisystem. Associations between the high-risk biomarker signature and two of the five 8-year incident disease classes were observed, implicating dysregulated immune and cardiometabolic pathways.
Conclusions
This study provides evidence that biomarker signatures and profiling of disease patterns can be used to risk stratify and identify ageing subpopulations that would benefit most from targeted preventative or secondary intervention strategies.
Publication and source details
Original title: An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts
Belinda Hernández; Eric Klopack; Frank Moriarty; Padraic Fallon; Nollaig Bourke; Eileen Crimmins; Rose-Anne Kenny; Cathal Mc Crory; Aisling O'Halloran
Age and Ageing · 2026
Address correspondence to: Belinda Hernández, The National Center for Pharmacoeconomics (NCPE), St James’s Hospital, Dublin, Ireland. Email: HERNANDB@tcd.ie© The Author(s) 2026. Published by Oxford University Press on behalf of the British Geriatrics Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Health Research Board10.13039/100010414 Atlantic Philanthropies10.13039/100004426 Irish Government Health Research Board10.13039/100010414 HRB ILP-PHR-2024-016Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:16:53.222571+00:00
DOI: 10.1093/ageing/afag135 · PMC13189271